PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)
PAD Profile : Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)
Keywords :
Chronic Obstructive Pulmonary Disease
Brand Names Include :
Daxas
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Tablets
Important Information :
Restricted to initiation by respiratory specialists in line with NICE TA461.
https://www.gov.uk/drug-safety-update/roflumilast-daxas-risk-of-suicidal-behaviour
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
04 October 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends roflumilast as a treatment option for COPD in line with NICE TA461
Roflumilast will be considered BLUE on the traffic light system with initiation by respiratory consultants.
There should be a minimum of 3 months prescribing in secondary care prior to transfer of care to primary care prescribers.
Associated BNF Codes
03. Respiratory System
03.03.03. Phosphodiesterase Type-4 inhibitors